Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
Authors' conclusion
The suspected association between GLP-1RA use and suicidality, as raised by the European Medicines Agency, was not found in our global analysis. This indicates that the sporadic reports of GLP-1RA-associated suicidality are likely influenced by factors such as comorbidities present in the GLP-1RA user population.
Study context
- Population
- Adverse drug reaction reports in the WHO pharmacovigilance database, 1967–2023, 170 countriestotal reports
- Participants
- 131,255,418 reports
- Exposure
- GLP-1 RA use vs other drugs, for suicidality reports
- Outcome
- Suicidality reports associated with GLP-1RA use (ROR with 95% CI; IC with IC025)
Methodological detailsdisproportionality analysis, WHO global pharmacovigilance database, adverse drug reaction reports 1967–2023, 170 countries
- Disproportionality analysis
- WHO global pharmacovigilance database
- Adverse drug reaction reports 1967–2023
- 170 countries
Main finding
As reported in the abstract
Suicidality with GLP-1RAs
| Group | Value | ROR | Information component (IC) |
|---|---|---|---|
| GLP-1RAs | 332 events | 0.15 (95% CI 0.13 to 0.16) | −2.77 (IC025 −2.95) |
GLP-1RAs
Value332 events
ROR0.15 (95% CI 0.13 to 0.16)
Information component (IC)−2.77 (IC025 −2.95)
Observational data: associations, not effects.
Further findings
- Suicidality with GLP-1RAs used for diabetes
- 0.13 (95% CI 0.11 to 0.14) · ROR · IC −2.95 (IC025 −3.14)
- Suicidality with GLP-1RAs used for obesity
- 0.44 (95% CI 0.34 to 0.58) · ROR · IC −1.16 (IC025 −1.62)
- Suicidality with other diabetes medications
- 1.13 (95% CI 1.10 to 1.15) · ROR · IC 0.17 (IC025 0.13)
- Suicidality with other obesity medications
- 1.08 (95% CI 1.01 to 1.14) · ROR · IC 0.10 (IC025 0.01)
Suicidality with other diabetes medications
- Association found
Suicidality with other obesity medications
- Potential association observed
Original publication
Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database. Diabetes Obes Metab. Published 19 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →